Search results
Added:
2 months ago
ACC 26 - Dr Paul Sorajja (Banner Health in Phoenix, Arizona, US) and Prof Lars Sondergaard (Chief Medical Officer and Divisional Vice President, Medical Affairs, Abbott) discuss the role of TriClip TEER in treating patients with severe tricuspid regurgitation and new data showcasing how TriClip TEER provides significant reduction in heart failure hospitalization relative to medical therapy…
View more
Added:
9 months ago
Source:
Transcatheter Academy
The long-term durability of complete revascularization in older patients with myocardial infarction (MI) and multivessel disease has been a subject of recent debate. New 3-year follow-up data from the Functional Assessment in Elderly MI Patients With Multivessel Disease (FIRE) trial show that the clinical benefits of a physiology-guided complete revascularization strategy are sustained over time…
View more
Added:
4 months ago
Source:
Radcliffe Cardiology
The long-term benefits of revascularization over medical therapy for patients with stable coronary artery disease (CAD) remain a subject of clinical debate. New long-term follow-up data from the Fractional Flow Reserve versus Angiography for Multivessel Evaluation 2 (FAME 2) trial provide further insight, demonstrating a sustained benefit for percutaneous coronary intervention (PCI) guided by…
View more
Added:
4 months ago
Source:
Radcliffe Vascular
The optimal management for asymptomatic carotid stenosis has been a subject of debate, particularly with advancements in medical therapy. New findings from the Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (CREST-2) provide clarity, suggesting a benefit for carotid-artery stenting when added to intensive medical management.¹MethodologyCREST-2 involved…
View more
Added:
4 months ago
Source:
Radcliffe Vascular
The optimal management for patients with high-grade asymptomatic carotid stenosis remains a key clinical question, particularly with advancements in medical therapy and revascularisation techniques. The CREST-2 trials were designed to assess whether adding revascularisation to intensive medical management provides a greater benefit than intensive medical management alone in this patient…
View more
Added:
3 months ago
Source:
ICR3 Journal Radcliffe Cardiology
The optimal timing for treating nonculprit lesions in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease remains a topic of clinical debate. The iMODERN trial sought to clarify this by comparing outcomes between an immediate, physiology-guided percutaneous coronary intervention (PCI) strategy and a deferred, imaging-guided approach.¹˒²MethodologyThe…
View more
Added:
9 months ago
Source:
Transcatheter Academy
The use of paclitaxel-coated devices did not reduce the rate of major amputations or death in patients with chronic limb-threatening ischaemia (CLTI) undergoing infrainguinal endovascular revascularisation, according to the results of a large registry-based trial.¹ While drug-coated devices are commonly used in peripheral interventions, their effect on amputation risk has been uncertain.²The…
View more
Added:
8 months ago
Learn about the definition and implications of a shock diagnosis and systems of care and the role of the shock team from Dr Frederick Welt (University of Utah, US).This three-part video lecture series, part of Women As One’s CLIMB® 2025 Skills Training Programme, offers case-based insights into Coronary and Mechanical Support for Cardiogenic Shock, curated by Dr Alison Duncan and Dr Frederick…
View more
Complete Revascularisation in STEMI: Do We Really Buy It?
Added:
1 month ago
Review Article
Complete Revascularisation Following Acute MI
Added:
1 year ago
Review Article